Moelans et al.[22] also used MLPA technique to compare genomic BIRC5 gene copy number changes in ductal carcinoma in situ and invasive ductal carcinoma, in which 20% of the patients with ductal carcinoma in situ type breast cancer and 12% of the patients with invasive ductal carcinoma type showed amplified BIRC5 gene copy number. This evidence concerns the gene BIRC5 and ductal breast carcinoma in situ.